Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan Laboratories Ltd.

Division of Mylan NV
mylanlabs.in

Latest From Mylan Laboratories Ltd.

Cipla Gears To Step In With Gx Kaletra Supplies For nCoV

Over half a dozen generic versions of AbbVie's Kaletra, currently part of treatment guidelines in China for nCoV-2019, are already on the Indian market and drug maker Cipla says it can make available around 12 million tablets of the combination. India has meanwhile just confirmed its first case of the coronavirus infection.

Generic Drugs Infectious Diseases

Hetero Launches India's First Generic Of Gilead’s Biktarvy

Hetero launches cut-price version of Gilead’s Biktarvy in India but 20 other India-based firms also hold licenses for the product. Gilead is entitled to a “modest royalty” on products produced under the voluntary license.

Launches Strategy

First Generic Of Gilead’s Biktarvy In India Debuts

Hetero launches cut-price version of Gilead’s Biktarvy in India but 20 other India-based firms also hold licenses for the product. Gilead is entitled to a “modest royalty” on products produced under the voluntary license.

Commercial Strategy

Strides Targets $200m-$400m From Injectables

Strides has set a sales target of $200m-$400m for Stelis’ generic injectables business in two to four years as part of its plan to reach $800m in total revenues in four years. Meanwhile, Stelis’ Rh-teriparatide for osteoporosis and sodium hyaluronate for osteoarthritis await Phase III incremental studies in the US.

Strategy Biosimilars
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Matrix Laboratories Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • India
  • Parent & Subsidiaries
  • Mylan NV
  • Senior Management
  • B. Hari Babu, PhD, CEO
  • Contact Info
  • Mylan Laboratories Ltd.
    Phone: (91) 40 30866666
    Plot No 564/A/22, Road No. 92
    Jubilee Hills
    Hyderabad , 500034
    India
UsernamePublicRestriction

Register